Mexico - Delayed Quote MXN
Mirum Pharmaceuticals, Inc. (MIRM.MX)
902.37
-89.81
(-9.05%)
At close: December 10 at 1:33:09 PM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 9 |
| Avg. Estimate | 107.83M | 112.71M | 448.56M | 522.11M |
| Low Estimate | 104.3M | 110.37M | 442.12M | 483.06M |
| High Estimate | 110.6M | 114.1M | 455.6M | 568.6M |
| Year Ago Sales | 77.88M | 90.38M | 336.89M | 448.56M |
| Sales Growth (year/est) | 38.47% | 24.71% | 33.15% | 16.40% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MIRM.MX | -- | -- | -- | -- |
| S&P 500 | 13.32% | 2.69% | 7.77% | 13.75% |
Upgrades & Downgrades
| Maintains | Raymond James: Strong Buy to Strong Buy | 5/13/2025 |
| Maintains | JMP Securities: Market Outperform to Market Outperform | 5/9/2025 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 2/28/2025 |
| Maintains | Baird: Outperform to Outperform | 2/27/2025 |
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 2/24/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |